LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

B. Besse, SH Lee, Shun Lü, Daniil Stroyakovskiy, O. Yazıcı, Jerónimo Rodríguez Cid, H. Hayashi, Danny Nguyen, James Chih‐Hsin Yang, Maya Gottfried, Ana Caroline Zimmer Gelatti, Scott Owen, S. Ou, Marguerite Ennis, Seema Sethi, J.M. Bauml, J. Zhang, J.C. Curtin, B.C. Cho